Tandem Diabetes Care Inc (TNDM) Stock Forecast & Price Target
Tandem Diabetes Care Inc · NASDAQ
$19.89-0.01 (-0.05%)
15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 20 firms covering Tandem Diabetes Care Inc, 10 rate it Buy or better, 10 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $15.50 to $55.00 (about 3.5x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $28.42 sits 43% above the current $19.89. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.18 next quarter toward $0.17 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS20 ratings
Moderate Buy
Strong Buy00%
Buy1050%
Hold1050%
Sell00%
Strong Sell00%
Based on 20 analysts giving stock ratings to Tandem Diabetes Care Inc.
As of Sep, 10 of 20 firms rate TNDM a Buy (10 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
TNDM EPS & revenue forecast
EPS · NEXT QUARTER
$0.18
Range $0.02 – $0.33 · 19 analysts · -1882% YoY
Next period, 19 analysts expect Tandem Diabetes Care Inc to earn $0.18 a share (range $0.02 – $0.33), versus $-0.01 a year earlier. Full-year consensus is $-0.67, growing to $0.17 the year after.
REVENUE · NEXT QUARTER
$304.1M
Range $292.3M – $315.0M · 19 analysts · +5% YoY
Revenue is expected to reach $304.1M (range $292.3M – $315.0M), +4.7% year-over-year. Full-year consensus is $1.1B, rising to $1.2B next year.
Top analysts covering Tandem Diabetes Care Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TNDM.
#1
Anthony Petrone
Mizuho · Rank #86
Hold
$20.00+0.6% to target
Overall win rate
46%
+ Follow
#2
Jonathan Block
Stifel · Rank #205
Hold
$22.00+10.6% to target
Overall win rate
41%
+ Follow
#3
William Plovanic
Canaccord Genuity · Rank #243
Buy
$35.00+76.0% to target
Overall win rate
37%
+ Follow
#4
Bruce Jackson
Benchmark · Rank #374
Hold
No targeton TNDM
Overall win rate
36%
+ Follow
#5
Frank Takkinen
Lake Street · Rank #394
Buy
$50.00+151.4% to target
Overall win rate
26%
+ Follow
TNDM stock forecast FAQ
What is TNDM's average 12-month price target?+
The 18 analysts with a live target average $28.42 for Tandem Diabetes Care Inc over the next 12 months, ranging from a $55.00 high to a $15.50 low.
Is TNDM stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 20 analyst ratings, 10 are Buy or Strong Buy, 10 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for TNDM?+
The Street-high target is $55.00 (Barclays), and the Street-low is $15.50 (Deutsche Bank). The average of all 18 active targets is $28.42.
How many Wall Street analysts cover TNDM?+
20 analysts have an active rating on Tandem Diabetes Care Inc, and 18 firms carry a live 12-month price target.
Who is the most accurate analyst covering TNDM?+
Among analysts who currently cover TNDM, Anthony Petrone of Mizuho has the strongest overall Quantellect track record (Rank #86). Their current call is Hold with a $20.00 target.
What is Tandem Diabetes Care Inc's projected EPS for next quarter?+
The consensus estimate is $0.18 per share (range $0.02 – $0.33) across 19 analysts. Full-year EPS is projected at $-0.67, rising to $0.17 the following year.
How much revenue is Tandem Diabetes Care Inc expected to report next quarter?+
Consensus revenue is $304.1M (range $292.3M – $315.0M). Full-year revenue is projected at $1.1B, growing to $1.2B next year.
Have analysts been upgrading or downgrading TNDM lately?+
As of Sep, 10 of 20 firms rate TNDM a Buy (10 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TNDM calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
RBC Capital
UBS
Deutsche Bank
